KDR and renal cell carcinoma: Sunitinib is an orally taken agent which is a multi-targeted tyrosine kinase inhibitor (TKIs) including vascular endothelial growth factor receptors (VEGFRs), like VEGFRs (VEGFR-1, VEGFR-2, and VEGFR-3) and c-Kit, etc, which are the mostly identified element in RCC pathogenesis and progress.[8] RCC is driven by angiogenesis and early hypoxia, in which angiogenesis is proved to be an independent prognostic factor.[9,10] Therefore, the neoadjuvant therapy combining the use of sunitinib and surgery has been put forward in the treatment of metastatic and advanced RCC.